Introduction
Amiodarone, an antiarrhythmic and anti-anginal agent, contains 75mg of organic iodine per 200mg active substance. The drug is deiodinated during its biotransformation, and it is estimated that a dose of 200mg releases 6mg of free iodine (Broekhuyzen et al., 1969) . Consequently, the thyroid gland has to adjust itself to these pharmacological quantities of iodine. When amiodarone medication is discontinued, it may take months until the iodine excess is cleared from the body due to the very long elimination half-life (approximately 40-60 days) (Haffajee et al., 1983; Plomp et al., 1984) . We will review the pharmacological and pathological effects of amiodarone on thyroid hormone metabolism, and discuss the relationship between the thyroidal effects of amiodarone and its mechanism of action.
Pharmacological effects of amiodarone on thyroid hormone metabolism Short-term amiodarone medication, up to 4 weeks, results in increased plasma thyroxine (T4), free thyroxine (FT4) and reverse triiodothyronine (rT3) concentrations and a decrease in plasma triiodothyronine (T3) and free triiodothyronine (FT3); these changes are accompanied with an increase of basal plasma thyrotropin (TSH) and peak TSH levels after TSHreleasing hormone (TRH), mostly within the normal range (Burger et al., 1976; Melmed et al., 1981) . Continuation of amiodarone medication is associated with a further rise in plasma T4, FT4 and rT3 and fall in plasma T3; TSH levels return gradually to pre-treatment values. A steady-state in hormone plasma concentrations is reached after 12-16 weeks (Melmed et al., 1981) . Amiodarone has no effect on plasma thyroxine-binding-globulin, nor does it interfere with the radioimmunoassays of thyroid hormones. Shortterm amiodarone treatment is associated with a decrease of T3 and T4 production rate (PR) and of T4 metabolic clearance rate (MCR); since the decrease in T4-MCR is relatively greater than the decrease in T4-PR, plasma T4 values increase (Lambert et al., 1982) . Long-term amiodarone treatment results in an increased T4-PR and a decreased T4-MCR (Lambert et al., 1982) . No data are available on rT3 kinetics in humans, but in rabbits rT3-MCR is decreased by amiodarone (Kannan et al., 1984) .
The initial decrease of T4-PR can be explained by a transient inhibition of thyroid hormone secretion by the iodine excess derived from amiodarone (Vagenakis et al., 1973) . The reduction in MCR of rT3 and T4 and the decrease in PR of T3 appears to be caused by inhibition of type 5-deiodinase, the enzyme that catalyses T4+T3 and rT3-* 3, 3'-T2 deiodination in liver. The generation ofT3 out ofadded T4 is markedly reduced in a dose-related manner in liver homogenates from rats pretreated in vivo with amiodarone (Balsam & Ingbar, 1978; Sogol et al., 1983) . If amiodarone is added in vitro the T3 production from T4 is inhibited when isolated rat hepatocytes are used (Aanderud et al., 1984) , but not when liver homogenates are used (Sogol et al., 1983) . This suggests that the effect of amiodarone is mediated via the plasma membrane. Indeed, amiodarone inhibits thyroid hormone uptake by rat hepatocytes in primary culture (Krenning et al., 1982) . One might therefore hypothesize that amiodarone primarily inhibits tissue uptake of thyroid hormones, notably in the liver. This would explain the decrease in rT3-MCR (the liver is an important site of rT3 degradation - Silva et al., 1982) , in T4-MCR (sequential deiodination of T4 is the major pathway of T4 degradation - Engler & Burger, 1984) , and in T3-PR (by decreased availability ofthe substrate T4 -the liver is a major production site of T3).
Pathological effects of amiodarone on thyroid hormone metabolism Diagnosis of amiodarone-induced thyrotoxicosis (AIT) and amiodarone-induced hypothyroidism (AIH)
Whereas the clinical and laboratory diagnosis of AIH poses no special problems, the diagnosis ofAIT can be very difficult. Firstly, the anti-adrenergic effects of amiodarone might moderate the clinical signs and symptoms of thyrotoxicosis. Secondly, the diagnostic accuracy of thyroid hormone assays in plasma is decreased, as is obvious from Figure 1 . Patients with an exaggerated TSH response to TRH had either a decreased plasma T4 (group III B, in all cases associated with overt myxoedema) or no decreased plasma T4 (group III A, associated with a clinically euthyroid state; these patients represent cases of subclinical hypothyroidism) (Evered et al., 1973 (Wiersinga et al., 1986) .
Incidence of AIT and AIH
In a prospective Belgian study (Chevigne-Brancart et al., 1983 ) the incidence of AIT was 15.3% and AIH 8.5%. Interestingly, 80% of the hypothyroid cases occurred in the first year of amiodarone treatment in contrast with 30% of the hyperthyroid cases; after discontinuation of amiodarone treatment no new cases ofhypothyroidism but five new cases of hyperthyroidism (17%) were observed within 6 months. An absent TSH response to TRH was encountered in 32% of patients who remained clinically euthyroid.
Another intriguing study related the incidence of amiodarone-induced dysthyroidism to dietary iodine intake (Martino et al., 1984b) : in iodine-deplete areas, AIT is more prevalent than AIH, whereas in iodinereplete areas there exists a preponderance of hypothyroid over hyperthyroid cases.
Pathogenesis of AIT and AIH
The pathogenesis of iodine-induced dysthyroidism is essentially unknown. The degree of iodine excess is similar in euthyroid, hyperthyroid and hypothyroid patients on long-term amiodarone therapy (Trip et al., 1983; Eason et al., 1984) and is therefore not the determinant per se. Some pre-existent thyroid abnormality may be unmasked by iodine excess, and the likelihood of such a mechanism in AIH is substantiated by its development relatively early in the course of treatment and by its preponderance in females (autoimmune thyroiditis is more common in women than in man). The precipitation of overt hyperthyroidism by iodine excess in patients with previous thyroid abnormalities is also well known (Fradkin & Wolff, 1983) , but it cannot be denied that iodide-induced hyperthyroidism also occurs in patients in whom, after recovery, thyroid function and regulation appears to be perfectly normal (Savoie et al., 1975 (Monteiro et al., 1986 ).
Treatment of AIT and AIH
Discontinuation of amiodarone medication is the most logical approach in the treatment of AIT and AIH, but is not always feasible because ofthe presence of cardiac disease requiring amiodarone treatment. The management ofAIH is relatively easy: withdrawal of amiodarone, and/or T4 substitution. Management of AIT is more difficult, mainly because of a lower effectiveness of antithyroid drugs and radioactive iodine during iodine excess. Thyroidectomy is a rigorous treatment for a self-limiting disease and may carry a high operative risk in these cardiac patients. Spontaneous cure in non-treated cases is observed within an average of 6 months; a phase of slight hypothyroidism precedes the return to euthyroidism (Leger et al., 1984) .
High doses of prednisone, up to 60mg/day, are reported to have a dramatic effect, with a return of plasma T4 and T3 to normal values in 2 weeks (Staubli et al., 1981; Wimpfheimer et al., 1982; Leger et al., 1984) . Recently, a combination of methimazole (40 mg/day) and potassium perchlorate (I g/day until euthyroidism is reached) has been advocated (Martino et al., 1984a) . Inhibition ofiodine uptake by perchlorate results in a greater effectiveness of methimazole, and 8 out of 9 patients thus treated were euthyroid within 45 days. Potassium perchlorate may also be useful in AIH: euthyroidism was reached in 3 months by discontinuation of amiodarone, but in 15-20 days if potassium perchlorate was given (Martino et al., 1985) .
Relation of thyroid hormone effects of amiodarone to its mechanism of action
The pharmacological actions of amiodarone include bradycardia, depression of myocardial oxygen consumption and lengthening of the cardiac action potential (Singh & Vaughan Williams, 1970) . The lengthening of the cardiac action potential can be prevented by concomitant administration of a physiological dose of T4 (Singh & Vaughan Williams, 1970) , and an identical change of cardiac action potentials has been observed in thyroidectomized rabbits (Freedberg et al., 1970) . Also, the electrocardiographic changes in amiodarone-treated patients resemble those in hypothyroid patients (Stauibli et al., 1981) . It has therefore been hypothesized that one of the mechanisms ofaction ofamiodarone is the induction ofa local 'hypothyroid-like' condition in the extrathyroidal tissues, notably in the heart (Freedberg et al., 1970) . A decreased production of T3 out of T4 by inhibition of 5'-iodiothyronine-deiodination might result in a decreased receptor occupancy of nuclear T3 receptors and thereby in modulation of postreceptor effects of T3 (e.g. the duration of the action potential). The hypothesis (Figure 2 ) could account for both the antianginal and anti-arrhythmic actions of the drug. In favour of this proposed mechanism is the decreased nuclear T3 receptor occupancy in livers of amiodarone-treated rats (own unpublished observations) and the antagonistic effect of amiodarone on nuclear binding of T3 in rat thyrotrophs in vitro (Franklyn et al., 1985) . The hypothesis is not supported by recent studies with iopanoic acid, a drug that also effectively inhibits the conversion ofT4 into T3 but had no antiarrhythmic activity in man (Meese et al., 1985) .
Indirect evidence for the hypothesis can be deduced from a study in patients with ventricular arrhythmias: an increase in basal and TRH-stimulated plasma TSH and a lengthening into the hypothyroid range of systolic time intervals was present in amiodaroneresponders but not in amiodarone-nonresponders (Beck-Peccoz et al., 1985) . Also, serum rT3 levels are correlated with amiodarone efficacy in the treatment of refractory arrhythmias (Nademanee et al., 1982; Gonska et al., 1985) , with serum amiodarone levels (Anastasiou-Nana et al., 1984) and with the QTc interval (Borghi et al., 1983 
